Viome and Scripps Research Develop At-Home RNA Test for Colon Cancer Prevention

Viome Life Sciences and Scripps Research have announced a strategic partnership to develop the first at-home RNA screening test designed to detect precancerous colon polyps, announced in a press release. This initiative aims to enhance colorectal cancer prevention by identifying molecular signals of polyps, offering improved sensitivity over existing at-home DNA tests.

The collaboration will involve a 1,000-patient clinical study, utilizing RNA-based stool and saliva tests to detect early warning signs of colorectal cancer. The study will leverage Viome's RNA sequencing and AI platform, combined with Scripps Research's clinical expertise, to train the system in identifying early molecular signs of polyp development.

The study will be conducted with patients undergoing routine colonoscopies at Scripps Health, where RNA data will be collected and analyzed to train predictive models. The goal is to develop a diagnostic test that can identify individuals at high risk of developing cancer without the need for invasive procedures. Upon successful validation, Viome plans to pursue a laboratory-developed test for distribution through licensed physicians.